NASDAQ: AURA - Aura Biosciences, Inc.

Rentabilidade por seis meses: -29.74%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção Aura Biosciences, Inc.

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa Aura Biosciences, Inc.

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial.

mais detalhes
The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

IPO date 2021-10-29
ISIN US05153U1079
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.aurabiosciences.com
Цена ао 5.99
Alteração de preço por dia: +5.39% (5.94)
Alteração de preço por semana: -16.53% (7.5)
Alteração de preço por mês: -16.53% (7.5)
Alteração de preço em 3 meses: -24.85% (8.33)
Mudança de preço em seis meses: -29.74% (8.91)
Mudança de preço por ano: -20.25% (7.85)
Mudança de preço em 3 anos: -70.42% (21.16)
Mudança de preço desde o início do ano: -24.85% (8.33)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 0 0
P/BV 1.58 8
P/E 0 0
EV/EBITDA -4 0
Total: 3.25

Eficiência

Nome Significado Nota
ROA, % -29.96 0
ROE, % -33.83 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.2337 10
Total: 8.6

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 0 0
Rentabilidade Ebitda, % 254.64 10
Rentabilidade EPS, % 10.83 2
Total: 6.4
Mais detalhes

Instituições Volume Compartilhar, %
Matrix Capital Management 6922870 13.98
Eventide Asset Management LLC 5802682 11.72
Adage Capital Partners GP L.L.C. 4225000 8.53
Citadel Advisors Llc 3631294 7.34
Medicxi Ventures Management (Jersey) Ltd 3039892 6.14
Nantahala Capital Management, LLC 2643720 5.34
Blackrock Inc. 2098745 4.24
Vanguard Group Inc 1730431 3.5
Decheng Capital Management III (Cayman), LLC 1163123 2.35
Goldman Sachs Group Inc 1037299 2.1

ETFCompartilhar, %Rentabilidade para o ano, %Dividendos, %
Range Cancer Therapeutics ETF 1.74943 47.24 0.11955
AltShares Event-Driven ETF 0.97581 9.61 1.21959
iShares Micro-Cap ETF 0.11218 17.09 1.54048
DBX ETF Trust - Xtrackers International Real Estate ETF 0.06228 -4.53 4.01983
Dimensional International Small Cap ETF 0.02439 5.69 3.34747
Avantis U.S Small Cap Equity ETF 0.02437 27.77 1.68271
FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund 0.01698 5.17 3.85434
Vanguard Russell 2000 ETF 0.01 17.16 1.48801
ProShares UltraPro Russell2000 0.00959 89.82 1.47873
Avantis International Equity ETF 0.0028 6.46 3.80856
ProShares Hedge Replication ETF 0.0027 5.92 1.47892
Dimensional World ex U.S. Core Equity 2 ETF 0.00213 13.06 3.62488
Dimensional International Core Equity 2 ETF 0.002 6.52 3.69996
Dimensional International Core Equity Market ETF 0.00084 13.09 3.48343
Dimensional US Core Equity Market ETF 0.00066 30.98 1.40618
iShares Russell 3000 ETF 0.00056 24.83 1.43482
Dimensional U.S. Equity ETF 0.0004 31.53 1.3557
Dimensional U.S. Core Equity 2 ETF 0.00024 30.76 1.47098
Vanguard Russell 3000 ETF 0 31.87 1.43817
0.1621.582.21



Supervisor Cargo Pagamento Ano de nascimento
Dr. Elisabet de los Pinos Ph.D. Founder, CEO, President & Director 895.16k 1974 (51 ano)
Ms. Julie B. Feder Chief Financial Officer 604.2k 1971 (54 ano)
Dr. Mark Plavsic D.V.M., Ph.D. Chief Technology Officer N/A 1961 (64 ano)
Mr. Patrick Nealon Senior Vice President of Clinical Development Operations N/A
Dr. Anthony Daniels M.D. Therapeutic Area Head of Ocular Oncology N/A
Dr. Richard Mountfield Ph.D. Senior Vice President of Regulatory Affairs & Quality N/A
Mr. Conor Kilroy General Counsel & Secretary N/A 1982 (43 ano)
Dr. Jill J. Hopkins M.D. Chief Medical Officer & President of Research and Development N/A 1965 (60 anos)

Endereço: United States, Boston. MA, 80 Guest Street - abrir no Google Maps, abrir mapas Yandex
Site: https://www.aurabiosciences.com